Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for LAURUSLABS
Revenue projections for LAURUSLABS

Investors are expected to be cautious with Laurus Labs Limited, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 1.224000
forwardPE 49.085938
debtToEquity 60.048000
earningsGrowth 2.104000
revenueGrowth 0.195000
grossMargins 0.533900
operatingMargins 0.180300
trailingEps 6.640000
forwardEps 23.370000

A current ratio of 1.224 for LAURUSLABS implies that the company has ample liquidity to meet its short-term debts. LAURUSLABS's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
LAURUSLABS's positive earnings and revenue growth suggest that the company is expected to expand its business. This reflects a healthy financial outlook, as LAURUSLABS's increasing profits and sales signal further growth in the near future.
LAURUSLABS's forward EPS being higher than its trailing EPS indicates that the company is expected to achieve greater profitability this financial year. This suggests improving earnings and a stronger financial position compared to the previous year's performance.

Price projections:

Price projections for LAURUSLABS
Price projections for LAURUSLABS

LAURUSLABS's price projections have steadily risen over time, pointing to increasing optimism about the company's prospects. This upward revision suggests that analysts expect LAURUSLABS to continue delivering solid performance in the future.

Recommendation changes over time:

Recommendations trend for LAURUSLABS
Recommendations trend for LAURUSLABS


Analysts have developed a sell bias for LAURUSLABS, urging caution for investors. It's essential to base investment decisions on multiple market indicators to avoid hasty conclusions. Relying on a broader scope of information will provide a more accurate assessment of LAURUSLABS's overall potential.